特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
953453

禁煙・ニコチン中毒治療の世界市場 - 業界動向と2027年までの予測

Global Smoking Cessation and Nicotine De-Addiction Market - Industry Trends and Forecast to 2027

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 324 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
禁煙・ニコチン中毒治療の世界市場 - 業界動向と2027年までの予測
出版日: 2020年07月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 324 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の禁煙・ニコチン中毒治療市場は、2020年~2027年の予測期間中に、CAGRで27.1%の成長が予測されています。

当レポートでは、世界の禁煙・ニコチン中毒治療市場について調査分析し、市場概要、セグメント別の市場分析、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第6章 世界の禁煙・ニコチン中毒治療市場:製品タイプ別

  • 概要
  • ニコチンあり
  • ニコチンなし

第7章 世界の禁煙・ニコチン中毒治療市場:治療タイプ別

  • 概要
  • 薬理学
  • 心理療法
  • その他

第8章 世界の禁煙・ニコチン中毒治療市場:流通経路別

  • 概要
  • オフライン
  • オンライン

第9章 世界の禁煙・ニコチン中毒治療市場:エンドユーザー別

  • 概要
  • ミレニアル世代
  • ジェネレーションZ
  • ジェネレーションX
  • サイレント世代

第10章 世界の禁煙・ニコチン中毒治療市場:地域別

  • 概要
  • アジア太平洋
    • 中国
    • 日本
    • 韓国
    • タイ
    • インドネシア
    • オーストラリア・ニュージーランド
    • マレーシア
    • インド
    • 香港
    • シンガポール
    • フィリピン
    • 台湾
    • その他のアジア太平洋
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • ロシア
    • スイス
    • スペイン
    • ベルギー
    • オランダ
    • トルコ
    • その他の欧州
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • イスラエル
    • 南アフリカ
    • エジプト
    • アラブ首長国連邦
    • その他の中東・アフリカ
  • 南米
    • アルゼンチン
    • ブラジル
    • その他の南米

第11章 世界の禁煙・ニコチン中毒治療市場:企業情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋
  • M&A
  • 新製品開発と承認
  • パートナーシップとその他の戦略的開発

第12章 SWOT分析と市場調査分析

  • SWOT分析
  • 市場調査分析

第13章 企業プロファイル

  • IMPERIAL BRANDS
  • 22ND CENTURY GROUP, INC.
  • PFIZER INC.
  • DR. REDDY'S LABORATORIES LTD.
  • GLAXOSMITHKLINE PLC.
  • ALKALON A/S
  • BRITISH AMERICAN TOBACCO
  • CAMBREX CORPORATION
  • CIPLA INC.
  • FERTIN PHARMA
  • JAPAN TOBACCO INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • PERRIGO COMPANY PLC
  • STRIDES CONSUMER PRIVATE LIMITED
  • TAKEDA CONSUMER HEALTHCARE COMPANY LIMITED

第14章 アンケート

第15章 結論

第16章 関連レポート

図表

LIST OF FIGURES

  • FIGURE 1 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SEGMENTATION 46
  • FIGURE 2 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: DATA TRIANGULATION 49
  • FIGURE 3 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: RESEARCH SNAPSHOT 50
  • FIGURE 4 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 51
  • FIGURE 5 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: COMPANY RESEARCH ANALYSIS 51
  • FIGURE 6 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: THE PRODUCT TYPE LIFE LINE CURVE 52
  • FIGURE 7 MULTIVARIATE MODELLING FOR GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET 53
  • FIGURE 8 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: INTERVIEW DEMOGRAPHICS 54
  • FIGURE 9 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: DBMR MARKET POSITION GRID 55
  • FIGURE 10 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: MARKET END-USER COVERAGE GRID 56
  • FIGURE 11 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: THE MARKET CHALLENGE MATRIX 58
  • FIGURE 12 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SEGMENTATION 64
  • FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE MARKET FOR SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET AND IS EXPECTED TO BE GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 65
  • FIGURE 14 GROWING AWARENESS AMONG POPULATION OWING TO INCREASING DISEASES FROM SMOKING IS A DRIVER OF SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 66
  • FIGURE 15 WITH NICOTINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET IN 2020 TO 2027 66
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES IN GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET 68
  • FIGURE 17 POPULATION OF ADULT E-CIGARETTES USERS, U.K.,2014-2019 (PERCENTAGE) 70
  • FIGURE 18 CHINA PREVELANCE RATE OF SMOKING, MALE VS FEMALE, 2015 (IN PERCENTAGE) 75
  • FIGURE 19 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE, 2019 79
  • FIGURE 20 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY TREATMENT TYPE, 2019 86
  • FIGURE 21 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY DISTRIBUTION CHANNEL, 2019 91
  • FIGURE 22 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY END-USER, 2019 95
  • FIGURE 23 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 103
  • FIGURE 24 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY REGION (2019) 104
  • FIGURE 25 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY REGION (2020 & 2027) 104
  • FIGURE 26 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY REGION (2019 & 2027) 105
  • FIGURE 27 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 105
  • FIGURE 28 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 107
  • FIGURE 29 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019) 108
  • FIGURE 30 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2020 & 2027) 108
  • FIGURE 31 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019 & 2027) 109
  • FIGURE 32 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 109
  • FIGURE 33 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 164
  • FIGURE 34 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019) 165
  • FIGURE 35 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2020 & 2027) 165
  • FIGURE 36 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019 & 2027) 166
  • FIGURE 37 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 166
  • FIGURE 38 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 212
  • FIGURE 39 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019) 213
  • FIGURE 40 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2020 & 2027) 213
  • FIGURE 41 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019 & 2027) 214
  • FIGURE 42 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 214
  • FIGURE 43 MIDDLE EAST AND AFRICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 231
  • FIGURE 44 MIDDLE EAST AND AFRICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019) 232
  • FIGURE 45 MIDDLE EAST AND AFRICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2020 & 2027) 232
  • FIGURE 46 MIDDLE EAST AND AFRICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019 & 2027) 233
  • FIGURE 47 MIDDLE EAST AND AFRICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 233
  • FIGURE 48 SOUTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: SNAPSHOT (2019) 260
  • FIGURE 49 SOUTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019) 261
  • FIGURE 50 SOUTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2020 & 2027) 261
  • FIGURE 51 SOUTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY COUNTRY (2019 & 2027) 262
  • FIGURE 52 SOUTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: BY PRODUCT TYPE (2020-2027) 262
  • FIGURE 53 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: COMPANY SHARE 2019 (%) 276
  • FIGURE 54 NORTH AMERICA SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: COMPANY SHARE 2019 (%) 277
  • FIGURE 55 EUROPE SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: COMPANY SHARE 2019 (%) 278
  • FIGURE 56 ASIA-PACIFIC SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET: COMPANY SHARE 2019 (%) 279
目次

Global Smoking cessation and nicotine de-addiction market is projected to register 27.1% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Smoking Cessation and Nicotine De-Addiction Market-By Product Type (with nicotine and without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Japan, China, South Korea, India, Australia and New Zealand, Tawian, Hong-Kong, Singapore, Thailand, Malaysia, Indonesia, Philippines, Brazil, Argentina, UAE, Saudi Arabia, Egypt, Israel, South Africa and many others)-Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the global smoking cessation and nicotine de-addiction market:

Growing adoption of e-cigarettes is expected to fuel the growth of the market

Growing awareness among population owing to increasing diseases from smoking

Market Players:

The key players of global smoking cessation and nicotine de-addiction market are:

Cipla Inc.

Johnson & Johnson Services, Inc

Takeda Consumer Healthcare Company Limited

Alkalon A/S

22nd Century Group, Inc.

GlaxoSmithKline plc.

Imperial Brands

Japan Tobacco Inc.

British American Tobacco

Perrigo Company plc

Fertin Pharma

Cambrex Corporation

Dr. Reddy's Laboratories Ltd.

Pfizer Inc.

Strides Pharma Science Limited

TABLE OF CONTENTS

1 INTRODUCTION 40

  • 1.1 OBJECTIVES OF THE STUDY 40
  • 1.2 MARKET DEFINITION 40
  • 1.3 OVERVIEW OF GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET 41
  • 1.4 LIMITATIONS 43
  • 1.5 MARKETS COVERED 43

2 MARKET SEGMENTATION 46

  • 2.1 MARKETS COVERED 46
  • 2.2 GEOGRAPHIC SCOPE 47
  • 2.3 YEARS CONSIDERED FOR THE STUDY 48
  • 2.4 CURRENCY AND PRICING 48
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
  • 2.6 PRODUCT TYPE LIFE LINE CURVE 52
  • 2.7 MULTIVARIATE MODELLING 53
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
  • 2.9 DBMR MARKET POSITION GRID 55
  • 2.10 MARKET END-USER COVERAGE GRID 56
  • 2.11 DBMR MARKET CHALLENGE MATRIX 58
  • 2.12 IMPORT-EXPORT DATA 59
  • 2.13 SECONDARY SOURCES 61
  • 2.14 ASSUMPTIONS 62

3 EXECUTIVE SUMMARY 63

4 PREMIUM INSIGHTS 66

5 MARKET OVERVIEW 67

  • 5.1 DRIVERS 69
    • 5.1.1 GROWING ADOPTION OF E-CIGARETTES IS EXPECTED TO FUEL THE GROWTH OF THE MARKET 69
    • 5.1.2 GROWING AWARENESS AMONG POPULATION OWING TO INCREASING DISEASES FROM SMOKING 71
    • 5.1.3 ANTI-SMOKING POLICIES BY GOVERNMENT IS EXPECTED TO BOOST THE MARKET 72
  • 5.2 RESTRAINTS 73
    • 5.2.1 ADVERSE EFFECTS OF SMOKING CESSATION PRODUCTS 73
    • 5.2.2 REGULATIONS ON E-CIGARETTES 74

  • 5.3 OPPORTUNITIES 75
    • 5.3.1 UNTAPPED ASIAN MARKET SUCH AS CHINA AND INDIA, AMONG OTHERS 75
    • 5.3.2 INHALERS AND SPRAYS CAN BE AN OPPORTUNITY FOR SMOKING CESSATION PRODUCTS 76
  • 5.4 CHALLENGE 77
    • 5.4.1 LACK OF AWARENESS IN RURAL AREAS 77

6 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, BY PRODUCT TYPE 78

  • 6.1 OVERVIEW 79
  • 6.2 WITH NICOTINE 81
      • 6.2.1.1 E-CIGARETTES 82
      • 6.2.1.2 NICOTINE PATCHES 82
      • 6.2.1.3 NICOTINE GUMS 82
      • 6.2.1.4 NICOTINE LOZENGES 82
        • 6.2.1.4.1 REGULAR LOZENGES 82
        • 6.2.1.4.2 MINI LOZENGES 82
        • 6.2.1.4.3 SUBLINGUAL LOZENGES 83
      • 6.2.1.5 NICOTINE TABLETS 83
  • 6.3 WITHOUT NICOTINE 83
      • 6.3.1.1 CHANTIX (VARENICLINE) 84
      • 6.3.1.2 CYTISINE 84
      • 6.3.1.3 ZYBAN (BUPROPION) 84

7 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, BY TREATMENT TYPE 85

  • 7.1 OVERVIEW 86
  • 7.2 PHARMACOLOGICAL 88
  • 7.3 THERAPIES 88
  • 7.4 OTHERS 89

8 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, BY DISTRIBUTION CHANNEL 90

  • 8.1 OVERVIEW 91
  • 8.2 OFFLINE 92
    • 8.2.1 DE-ADDICTION CENTERS 92
    • 8.2.2 HOSPITAL PHARMACIES 92
    • 8.2.3 RETAIL PHARMACIES 93
    • 8.2.4 RETAIL STORES 93
    • 8.2.5 OTHERS 93
  • 8.3 ONLINE 93

9 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, BY END-USER 94

  • 9.1 OVERVIEW 95
  • 9.2 MILLENNIALS 97
  • 9.3 MILLENNIALS END-USER, BY PRODUCT TYPE 97
    • 9.3.1 WITH NICOTINE 97
    • 9.3.2 WITHOUT NICOTINE 97
  • 9.4 GENERATION Z 98
  • 9.5 GENERATION Z END-USER, BY PRODUCT TYPE 98
    • 9.5.1 WITH NICOTINE 98
    • 9.5.2 WITHOUT NICOTINE 98
  • 9.6 GENERATION X 99
  • 9.7 GENERATION X END-USER, BY PRODUCT TYPE 99
    • 9.7.1 WITH NICOTINE 99
    • 9.7.2 WITHOUT NICOTINE 99
  • 9.8 SILENT GENERATION 100
  • 9.9 SILENT GENERATION END-USER, BY PRODUCT TYPE 100
    • 9.9.1 WITH NICOTINE 100
    • 9.9.2 WITHOUT NICOTINE 100

10 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, BY GEOGRAPHY 101

  • 10.1 OVERVIEW 102
  • 10.2 ASIA-PACIFIC 107
    • 10.2.1 CHINA 115
    • 10.2.2 JAPAN 119
    • 10.2.3 SOUTH KOREA 123
    • 10.2.4 THAILAND 127
    • 10.2.5 INDONESIA 131
    • 10.2.6 AUSTRALIA AND NEWZELAND 135
    • 10.2.7 MALAYSIA 139
    • 10.2.8 INDIA 143
    • 10.2.9 HONG KONG 147
    • 10.2.10 SINGAPORE 151
    • 10.2.11 PHILIPPINES 155
    • 10.2.12 TAIWAN 159
    • 10.2.13 REST OF ASIA-PACIFIC 163

  • 10.3 EUROPE 164
    • 10.3.1 U.K. 172
    • 10.3.2 GERMANY 176
    • 10.3.3 FRANCE 180
    • 10.3.4 ITALY 183
    • 10.3.5 RUSSIA 187
    • 10.3.6 SWITZERLAND 191
    • 10.3.7 SPAIN 195
    • 10.3.8 BELGIUM 199
    • 10.3.9 NETHERLANDS 203
    • 10.3.10 TURKEY 207
    • 10.3.11 REST OF EUROPE 211
  • 10.4 NORTH AMERICA 212
    • 10.4.1 U.S. 219
    • 10.4.2 CANADA 223
    • 10.4.3 MEXICO 227
  • 10.5 MIDDLE EAST AND AFRICA 231
    • 10.5.1 SAUDI ARABIA 239
    • 10.5.2 ISRAEL 243
    • 10.5.3 SOUTH AFRICA 247
    • 10.5.4 EGYPT 251
    • 10.5.5 U.A.E. 255
    • 10.5.6 REST OF MIDDLE EAST AND AFRICA 259
  • 10.6 SOUTH AMERICA 260
    • 10.6.1 ARGENTINA 267
    • 10.6.2 BRAZIL 271
    • 10.6.3 REST OF SOUTH AMERICA 275

11 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION MARKET, COMPANY LANDSCAPE 276

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL 276
  • 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 277
  • 11.3 COMPANY SHARE ANALYSIS: EUROPE 278
  • 11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 279
  • 11.5 MERGERS & ACQUISITIONS 279
  • 11.6 NEW PRODUCT DEVELOPMENT & APPROVALS 280
  • 11.7 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS 281

12 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS 282

  • 12.1 SWOT ANALYSIS 282
    • 12.1.1 STRENGTH: STRONG GEOGRAPHICAL PRESENCE 282
    • 12.1.2 WEAKNESS: LIMTED PRODUCT PORTFOLIO 282
    • 12.1.3 OPPORTUNITY: INCREASING INVESTMENT IN R&D EXPENDITURE 283
    • 12.1.4 THREAT: STRINGENT RULES AND REGULATIONS 283
  • 12.2 DATABRIDGE MARKET RESEARCH ANALYSIS 284

13 COMPANY PROFILE 285

  • 13.1 IMPERIAL BRANDS 285
    • 13.1.1 COMPANY SNAPSHOT 285
    • 13.1.2 REVENUE ANALYSIS 286
    • 13.1.3 COMPANY SHARE ANALYSIS 286
    • 13.1.4 PRODUCT PORTFOLIO 287
    • 13.1.5 RECENT UPDATE 287
  • 13.2 22ND CENTURY GROUP, INC. 288
    • 13.2.1 COMPANY SNAPSHOT 288
    • 13.2.2 REVENUE ANALYSIS 288
    • 13.2.3 COMPANY SHARE ANALYSIS 289
    • 13.2.4 PRODUCT PORTFOLIO 289
    • 13.2.5 RECENT UPDATES 289
  • 13.3 PFIZER INC. 290
    • 13.3.1 COMPANY SNAPSHOT 290
    • 13.3.2 REVENUE ANALYSIS 291
    • 13.3.3 COMPANY SHARE ANALYSIS 291
    • 13.3.4 BRAND PORTFOLIO 292
    • 13.3.5 RECENT UPDATE 292
  • 13.4 DR. REDDY'S LABORATORIES LTD. 293
    • 13.4.1 COMPANY SNAPSHOT 293
    • 13.4.2 REVENUE ANALYSIS 294
    • 13.4.3 COMPANY SHARE ANALYSIS 294
    • 13.4.4 BRAND PORTFOLIO 295
    • 13.4.5 RECENT UPDATE 295
  • 13.5 GLAXOSMITHKLINE PLC. 296
    • 13.5.1 COMPANY SNAPSHOT 296
    • 13.5.2 REVENUE ANALYSIS 297
    • 13.5.3 COMPANY SHARE ANALYSIS 297
    • 13.5.4 PRODUCT PORTFOLIO 298
    • 13.5.5 RECENT UPDATE 298

  • 13.6 ALKALON A/S 299
    • 13.6.1 COMPANY SNAPSHOT 299
    • 13.6.2 PRODUCT PORTFOLIO 299
    • 13.6.3 RECENT UPDATE 299
  • 13.7 BRITISH AMERICAN TOBACCO 300
    • 13.7.1 COMPANY SNAPSHOT 300
    • 13.7.2 REVENUE ANALYSIS 301
    • 13.7.3 PRODUCT PORTFOLIO 301
    • 13.7.4 RECENT UPDATES 302
  • 13.8 CAMBREX CORPORATION 303
    • 13.8.1 COMPANY SNAPSHOT 303
    • 13.8.2 PRODUCT PORTFOLIO 303
    • 13.8.3 RECENT UPDATE 303
  • 13.9 CIPLA INC. 304
    • 13.9.1 COMPANY SNAPSHOT 304
    • 13.9.2 REVENUE ANALYSIS 305
    • 13.9.3 BRAND PORTFOLIO 305
    • 13.9.4 RECENT UPDATE 306
  • 13.10 FERTIN PHARMA 307
    • 13.10.1 COMPANY SNAPSHOT 307
    • 13.10.2 PRODUCT PORTFOLIO 307
    • 13.10.3 RECENT UPDATE 307
  • 13.11 JAPAN TOBACCO INC. 308
    • 13.11.1 COMPANY SNAPSHOT 308
    • 13.11.2 REVENUE ANALYSIS 309
    • 13.11.3 PRODUCT PORTFOLIO 309
    • 13.11.4 RECENT UPDATE 310
  • 13.12 JOHNSON & JOHNSON SERVICES, INC. 311
    • 13.12.1 COMPANY SNAPSHOT 311
    • 13.12.2 REVENUE ANALYSIS 312
    • 13.12.3 PRODUCT PORTFOLIO 312
    • 13.12.4 RECENT UPDATE 312
  • 13.13 PERRIGO COMPANY PLC 313
    • 13.13.1 COMPANY SNAPSHOT 313
    • 13.13.2 REVENUE ANALYSIS 314
    • 13.13.3 PRODUCT PORTFOLIO 314
    • 13.13.4 RECENT UPDATE 315

  • 13.14 STRIDES CONSUMER PRIVATE LIMITED 316
    • 13.14.1 COMPANY SNAPSHOT 316
    • 13.14.2 REVENUE ANALYSIS 316
    • 13.14.3 PRODUCT PORTFOLIO 317
    • 13.14.4 RECENT UPDATES 317
  • 13.15 TAKEDA CONSUMER HEALTHCARE COMPANY LIMITED 318
    • 13.15.1 COMPANY SNAPSHOT 318
    • 13.15.2 PRODUCT PORTFOLIO 318
    • 13.15.3 RECENT UPDATE 318

14 QUESTIONNAIRE 319

15 CONCLUSION 323

16 RELATED REPORTS 324

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.